These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 30037689)

  • 21. Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE).
    Carlson KV; Rovner ES; Nair KV; Deal AS; Kristy RM; Schermer CR
    Adv Ther; 2019 Aug; 36(8):1906-1921. PubMed ID: 31222714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multicenter prospective study for overactive bladder patient treatment satisfaction with mirabegron after being unsatisfied with antimuscarinic therapy (FAVOR study).
    Ko KJ; Choo MS; Chang YS; Kim JC; Lee KS
    Neurourol Urodyn; 2020 Nov; 39(8):2417-2424. PubMed ID: 32894793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post-marketing surveillance study.
    Kato D; Tabuchi H; Uno S
    Low Urin Tract Symptoms; 2019 Apr; 11(2):O152-O161. PubMed ID: 30079630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Higher urge severity score predicts resumption of overactive bladder (OAB) medication following discontinuation of mirabegron treatment in patients with OAB.
    Wang CC; Jiang YH; Kuo HC
    Low Urin Tract Symptoms; 2019 Apr; 11(2):O180-O185. PubMed ID: 30565417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.
    Ng DB; Espinosa R; Johnson SJ; Walker D; Gooch K
    J Med Econ; 2017 Dec; 20(12):1272-1280. PubMed ID: 28805473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient-reported outcomes with the β
    Khullar V; Amarenco G; Angulo JC; Blauwet MB; Nazir J; Odeyemi IA; Hakimi Z
    Neurourol Urodyn; 2016 Nov; 35(8):987-994. PubMed ID: 26288118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study).
    Yamanishi T; Kaga K; Sakata K; Yokoyama T; Kageyama S; Fuse M; Tokunaga S
    Neurourol Urodyn; 2020 Feb; 39(2):804-812. PubMed ID: 31961963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
    Kobayashi M; Nukui A; Kamai T
    Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mirabegron: a Beta-3 agonist for overactive bladder.
    Bragg R; Hebel D; Vouri SM; Pitlick JM
    Consult Pharm; 2014 Dec; 29(12):823-37. PubMed ID: 25521658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments.
    Bunniran S; Davis C; Kristy R; Ng D; Schermer CR; Uribe C; Suehs BT
    Neurourol Urodyn; 2018 Jan; 37(1):177-185. PubMed ID: 28370541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of transcutaneous electrical nerve stimulation combined with mirabegron therapy compared with mirabegron monotherapy for overactive bladder: a prospective randomized controlled study.
    Zhao L; Wu F; Wang J; Wang Y; Peng W; Chen Y
    World J Urol; 2024 Jun; 42(1):370. PubMed ID: 38847900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cure effect and persistence of treatment with Mirabegron in patients with symptoms of overactive bladder: a multicentre clinical study].
    Martan A; Mašata J; Švabík K; Hanuš T; Krhut J; Zachoval R
    Ceska Gynekol; 2017; 82(6):424-429. PubMed ID: 29302974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study.
    Kim SC; Park M; Chae C; Yoon JH; Kwon T; Park S; Moon KH; Cheon SH; Park S
    Investig Clin Urol; 2021 May; 62(3):317-323. PubMed ID: 33834641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The safety and effectiveness of mirabegron in Parkinson's disease patients with overactive bladder: a randomized controlled trial.
    Moussa M; Chakra MA; Dabboucy B; Fares Y; Dellis A; Papatsoris A
    Scand J Urol; 2022 Feb; 56(1):66-72. PubMed ID: 34672847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada.
    Hakimi Z; Nazir J; McCrea C; Berling M; Fatoye F; Ramos B; Wagg A
    J Med Econ; 2017 Jun; 20(6):614-622. PubMed ID: 28286993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response.
    Culha MG; Degirmentepe RB; Ozbir S; Cakir SS; Homma Y
    Int Urogynecol J; 2019 Dec; 30(12):2121-2126. PubMed ID: 31332467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [MIRABEGRON--A NEW DRUG FOR TREATMENT OF OVERACTIVE BLADDER].
    Kasjan GR
    Urologiia; 2015; (4):121-4. PubMed ID: 26665779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies.
    Matsukawa Y; Takai S; Majima T; Funahashi Y; Sassa N; Kato M; Yamamoto T; Gotoh M
    Neurourol Urodyn; 2019 Mar; 38(3):941-949. PubMed ID: 30779375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of mirabegron and imidafenacin for efficacy and safety in Japanese female patients with overactive bladder: A randomized controlled trial (COMFORT study).
    Otsuka A; Kageyama S; Suzuki T; Matsumoto R; Nagae H; Kitagawa M; Furuse H; Ozono S
    Int J Urol; 2016 Dec; 23(12):1016-1023. PubMed ID: 27686226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.
    Chapple CR; Siddiqui E
    Expert Rev Clin Pharmacol; 2017 Feb; 10(2):131-151. PubMed ID: 28001447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.